Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Inc. (BIIB) reported $2.43 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 6.1%. EPS of $3.02 for the same period compares to $3.67 a year ago.The reported revenue represents a surprise of +8.91% over the Zacks Consensus Estimate of $2.23 billion. With the consensus EPS estimate being $3.26, the EPS surprise was -7.36%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product- Rare Disease- SKYCLARYS - Rest of World: $54.80 million compared to the $33.02 million average estimate based on 22 analysts. Revenue- Product- Rare Disease- SKYCLARYS - United States: $69.10 million versus $74.12 million estimated by 22 analysts on average. Revenue- Product- Rare Disease- SPINRAZA- United States: $154.40 million versus $160.72 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +4% change. Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States: $39.80 million versus $31.40 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -8.9% change. Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $381.50 million compared to the $364.47 million average estimate based on 26 analysts. The reported number represents a change of -11.6% year over year. Revenue- Product- Rare Disease- SPINRAZA- Total: $423.90 million versus the 26-analyst average estimate of $365 million. The reported number represents a year-over-year change of +24.2%. Revenue- Anti-CD20 therapeutic programs: $378 million versus $411.57 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change. Revenue- Product- Rare Disease- SKYCLARYS- Total: $123.90 million versus the 25-analyst average estimate of $107.53 million. Revenue- Product, net: $1.73 billion versus $1.66 billion estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change. Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Total: $206.10 million versus the 24-analyst average estimate of $201.12 million. The reported number represents a year-over-year change of -19%. Revenue- Product- Multiple Sclerosis (MS)- Total: $953 million versus $925.29 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -11.4% change. Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $138.80 million versus the 24-analyst average estimate of $141.23 million. The reported number represents a year-over-year change of +8.9%. View all Key Company Metrics for Biogen here>>>Shares of Biogen have returned -7.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks